During the 12th Annual Scientific Sessions (January 29 to February 1, 2009) of the Society for Cardiovascular Magnetic Resonance (SCMR), the world's major international society for cardiovascular imaging, the role of magnetic resonance imaging to assess the effect of therapy in patients with acute myocardial infarction will be demonstrated in a series of papers. Cardiovascular magnetic resonance imaging offers the ability to measure after therapy the size a myocardial infarction would have had if no therapy had been performed (Salvage-imaging). This allows physicians to assess the effect of their intervention and thus, to perform studies to optimize the benefit to their patients.
Before this new technique became available, this knowledge could only be generated to compare large groups of patients who underwent different treatment regimes to average the differences between the groups. With the new technique, these differences can now be corrected for and thus much faster progress towards individually optimized therapy can be
generated.
"Using the new magnetic resonance technique we have been able to show in a relatively small trial of 220 patients, that therapy in patients after myocardial infarction can be optimized adding antioxidative agents to standard therapy," said Holger Thiele, MD, from the University of Leipzig, Germany. "We had known this from animal data before and were now
able to demonstrate this effect in patients using magnetic resonance imaging as an endpoint."
Magnetic resonance imaging has already been established as an endpoint for cardiac function, size and measuring the size of irreversible myocardial damage after myocardial infarction. It is now expanding to a further endpoint for myocardial salvage in patients with acute myocardial infarction.
About the Society for Cardiovascular Magnetic Resonance (SCMR)
Founded in 1994, SCMR is a professional association whose vision is to be the recognized representative and advocate for physicians, scientists and technologists who work in the field of cardiovascular magnetic resonance. SCMR endeavors to be the principal international, independent organization committed to the further development of cardiovascular magnetic resonance through education, quality control, research, and training. For more information, visit www.scmr.org.
Business & Industry
- Bayer launches unit to develop new precision health consumer products
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
- Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
- FDA Advisory Committee votes in support of approval for Pfizer's vaccine candidate to help prevent RSV in infants through maternal immunization
- Thermo Fisher Scientific & Pfizer partner to expand localized access to next generation sequencing-based testing for cancer patients in international markets
Research & Development
- Researchers use ‘natural’ system to identify proteins most useful for developing an effective HIV vaccine
- New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer's disease
- Large study provides scientists with deeper insight into long COVID symptoms
- Multivitamin improves memory in older adults, study finds
- Capturing transporter structure paves the way for drug development
- Delivering on the promise of personalized breast cancer therapy
- Researchers identify 10 pesticides toxic to neurons involved in Parkinson's
Conferences & Events
- Reduced cancer mortality with daily vitamin D intake
- Driving the potential of gene-based medicine through cutting-edge technologies to target undruggable diseases
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease
- FDA approves first respiratory syncytial virus (RSV) vaccine
- FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation
- FDA approves first over-the-counter naloxone nasal spray
- FDA grants Accelerated Approval for Alzheimer's disease treatment